LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%Julie R. Brahmer, Martin Reck, AE Robinson et al.|Annals of Oncology|2020Cited by 96